SeekingAlpha · Aug 18, 2026
NASDAQ · CERS
Cerus Corporation
Healthcare · Medical - Devices
$2.53
Up+$0.03 (+1.20%)
Updated Sep 17, 2026, 12:04 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 414.62M
- P/E ratio
- -21.89
- Dividend yield
- 0.00%
- 52-week range
- $1.20 – $3.47
- Volume
- 1.46M
- Avg. volume
- 1.42M
Price performance
CERS price history
1M range · 20 trading sessions · Daily adjusted prices
CERS closed at $2.53 after 20 trading sessions, down 11.23% for the selected period.
- Last close
- $2.53
- Period change
- -11.23%
- Period low
- $2.46
- Period high
- $2.85
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $2.50 | $2.58 | $2.50 | $2.53 | 1.46M |
| Sep 15, 2026 | $2.55 | $2.55 | $2.49 | $2.50 | 1.02M |
| Sep 14, 2026 | $2.46 | $2.57 | $2.45 | $2.55 | 1.35M |
| Sep 11, 2026 | $2.50 | $2.51 | $2.45 | $2.49 | 1.55M |
| Sep 10, 2026 | $2.49 | $2.515 | $2.46 | $2.46 | 750.8K |
| Sep 9, 2026 | $2.53 | $2.54 | $2.50 | $2.51 | 874.62K |
| Sep 8, 2026 | $2.56 | $2.58 | $2.525 | $2.54 | 753.45K |
| Sep 4, 2026 | $2.56 | $2.60 | $2.54 | $2.59 | 1.1M |
| Sep 3, 2026 | $2.64 | $2.665 | $2.5209 | $2.57 | 917.12K |
| Sep 2, 2026 | $2.63 | $2.69 | $2.56 | $2.60 | 1.57M |
| Sep 1, 2026 | $2.60 | $2.64 | $2.57 | $2.61 | 1.08M |
| Aug 31, 2026 | $2.63 | $2.67 | $2.56 | $2.64 | 1.32M |
| Aug 28, 2026 | $2.70 | $2.73 | $2.63 | $2.65 | 1.68M |
| Aug 27, 2026 | $2.71 | $2.79 | $2.71 | $2.72 | 810.57K |
| Aug 26, 2026 | $2.69 | $2.755 | $2.68 | $2.74 | 1.1M |
| Aug 25, 2026 | $2.69 | $2.78 | $2.69 | $2.72 | 831.2K |
| Aug 24, 2026 | $2.81 | $2.82 | $2.69 | $2.69 | 1.62M |
| Aug 21, 2026 | $2.81 | $2.87 | $2.78 | $2.81 | 2.49M |
| Aug 20, 2026 | $2.82 | $2.89 | $2.77 | $2.79 | 2.61M |
| Aug 19, 2026 | $2.8477 | $2.91 | $2.795 | $2.85 | 1.6M |
Latest CERS news
The latest Smart Investors Daily articles mentioning CERS.
Stock researchCompany · Overview
CERS research
Overview
Company profile and research snapshot.
Company profile
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $4.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | Freedom Broker | Buy | — |
| May 1, 2026 | BTIG | Buy | — |
| Feb 21, 2025 | Cantor Fitzgerald | Overweight | — |
| Oct 17, 2024 | Stifel | Buy | — |
| May 3, 2024 | Cantor Fitzgerald | Overweight | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 8, 2026
Cerus Corporation 2026 Q2 - Results - Earnings Call Presentation
2026-08-08. The following slide deck was published by Cerus Corporation in conjunction with their 2026 Q2 earnings call.
SeekingAlpha · Jul 30, 2026
Cerus Corporation (CERS) Q2 2026 Earnings Call Transcript
Cerus Corporation (CERS) Q2 2026 Earnings Call July 30, 2026 4:30 PM EDTCompany ParticipantsTimothy Lee - Head of Investor RelationVivek Jayaraman - CEO,...
ChartMill · Jul 30, 2026
Cerus Corp (NASDAQ:CERS) Drops 10% After Q2 Revenue Beat Overshadowed by Lowered Full-Year Guidance
Cerus Corp Q2 revenue beat estimates but stock fell 10% after hours on weaker full-year product guidance, citing margin pressure and lower government revenue.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
